NEWTOWN SQUARE, PA — ArriVent BioPharma, Inc. (Nasdaq: AVBP) has announced the appointment of Merdad Parsey, M.D., Ph.D., to its Board of Directors. A respected leader in global clinical development, Dr. Parsey brings a distinguished track record, including his most recent position as Chief Medical Officer and Executive Vice President at Gilead Sciences, Inc.
Dr. Parsey’s wealth of experience spans some of the biopharmaceutical industry’s most influential companies. He previously held leadership roles at Genentech, Inc., where he oversaw clinical development and operational functions as Senior Vice President in Research and Early Development. His career also includes key roles at Sepracor, Inc., Regeneron Pharmaceuticals, Inc., and Merck, Inc. Early in his career, Dr. Parsey served as an Assistant Professor of Medicine and Director of Critical Care Medicine at NYU School of Medicine.
“Dr. Parsey is a seasoned executive who has driven therapeutic innovation and strategic growth at prominent pharmaceutical and biotech companies across a broad array of therapeutic areas,” said Bing Yao, Chairman and CEO of ArriVent. “We are thrilled to have him join our Board of Directors at this important time and leverage his experience as firmonertinib progresses towards registration and we advance our antibody drug conjugate (ADC) pipeline.”
Dr. Parsey expressed enthusiasm about contributing to ArriVent’s mission, stating, “ArriVent is poised to broadly change the cancer treatment landscape with differentiated candidates like firmonertinib that address key unmet needs and their pipeline of next-generation ADC programs that use diverse approaches. I am excited to partner with management and the Board of Directors to help shape the clinical development and commercial strategy for their growing portfolio.”
Dr. Parsey’s appointment aligns with ArriVent’s focus on developing innovative, targeted cancer therapies. His extensive expertise and leadership are expected to bolster the company’s strategic direction as it progresses its lead assets and expands its oncology portfolio.
For the latest news on everything happening in Chester County and the surrounding area, be sure to follow MyChesCo on Google News and MSN.